Eye problems in breast cancer patients treated with tamoxifen View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-03

AUTHORS

Annlia Paganini-Hill, Linda J Clark

ABSTRACT

BACKGROUND: Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems. METHODS: We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55-72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57-75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4-5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis. FINDINGS: Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94-2.10) for standard-term users and 1.70 (1.11-2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results. INTERPRETATION: Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams. More... »

PAGES

167-172

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1006342300291

DOI

http://dx.doi.org/10.1023/a:1006342300291

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053062817

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/10845279


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cataract", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Eye Diseases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Southern California", 
          "id": "https://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Paganini-Hill", 
        "givenName": "Annlia", 
        "id": "sg:person.01032313301.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032313301.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southern California", 
          "id": "https://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Clark", 
        "givenName": "Linda J", 
        "id": "sg:person.01334140055.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334140055.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1172/jci117514", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018622434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0161-6420(96)30431-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039249711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0042-6989(94)90099-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039738451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0042-6989(94)90099-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039738451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9394(99)80190-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049049615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/90.18.1371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049883062"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006254-200007000-00022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060260386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006254-200007000-00022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060260386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00006254-200007000-00022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1060260386"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081767724", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082773348", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1996.14.3.1018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082882762"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083051131", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2000-03", 
    "datePublishedReg": "2000-03-01", 
    "description": "BACKGROUND: Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems.\nMETHODS: We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55-72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57-75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4-5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis.\nFINDINGS: Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94-2.10) for standard-term users and 1.70 (1.11-2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results.\nINTERPRETATION: Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1023/a:1006342300291", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435384", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "60"
      }
    ], 
    "name": "Eye problems in breast cancer patients treated with tamoxifen", 
    "pagination": "167-172", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fcc040a36559c19b4d5bc426f40477dc0236d46a2f94e2e29c1790b94065afee"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "10845279"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1006342300291"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053062817"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1006342300291", 
      "https://app.dimensions.ai/details/publication/pub.1053062817"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T14:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8660_00000501.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1023/A:1006342300291"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1006342300291'


 

This table displays all metadata directly associated to this object as RDF triples.

157 TRIPLES      21 PREDICATES      52 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1006342300291 schema:about N01d1127c67d2487eb3ea22969f8b5049
2 N094cd4ea599c42f9bcb472c2ab72e622
3 N19787cf257cc4bc088e9c30366ea45c1
4 N21af17255b354a038d2406c188db2abb
5 N4d432ef656f84dd1bafe1537c1d8beac
6 N58aebe3050354f03a8a85684ab93c2de
7 N73e636f6294446ef980bcd2ab12e2a78
8 N74c5220cf7b542d2bcba6059111ab061
9 Nbaad2ec05ff8489c9a828d99a285eaa7
10 Nbda3adc2fc9e4dee9ed65dcdd3b40497
11 Nbe028a703c4843f1b92e98266a777abb
12 Ncb5ca8143ab3498a935f2b92bbe71a52
13 Ndc4f845b77a348b786f3b2620d0c9d55
14 anzsrc-for:11
15 anzsrc-for:1117
16 schema:author Nfeee8d56457b4e79b3c1e7ada06e4961
17 schema:citation https://app.dimensions.ai/details/publication/pub.1081767724
18 https://app.dimensions.ai/details/publication/pub.1082773348
19 https://app.dimensions.ai/details/publication/pub.1083051131
20 https://doi.org/10.1016/0042-6989(94)90099-x
21 https://doi.org/10.1016/s0002-9394(99)80190-1
22 https://doi.org/10.1016/s0161-6420(96)30431-4
23 https://doi.org/10.1093/jnci/90.18.1371
24 https://doi.org/10.1097/00006254-200007000-00022
25 https://doi.org/10.1172/jci117514
26 https://doi.org/10.1200/jco.1996.14.3.1018
27 schema:datePublished 2000-03
28 schema:datePublishedReg 2000-03-01
29 schema:description BACKGROUND: Tamoxifen is an oral anti-estrogen used in the treatment of breast cancer and recently approved to reduce the incidence of breast cancer in high risk women. As a large clinical trial of tamoxifen has reported an increased risk of cataract, we conducted a study of women with breast cancer to evaluate the association of tamoxifen with cataracts and other eye problems. METHODS: We attempted to recruit previously interviewed patients who were cases in a population-based case-control study of 2653 women with primary breast cancer diagnosed between 1987 and 1996 at ages 55-72 years in Los Angeles County, California, USA. In November 1997, each case was mailed a questionnaire to ascertain self-reported incidence of eye diseases and Amsler grid test scores. Information from 1297 women aged 57-75 years of age was analyzed. Women reporting treatment with tamoxifen were categorized as standard-term users (4-5 years), short-term users (<4 years), or long-term users (6+ years) and compared to non-users. All p-values, relative risks, and confidence intervals for differences in eye problems and grid test results are adjusted for age and stage of disease at diagnosis. FINDINGS: Standard-term and long-term users of tamoxifen more frequently reported developing cataracts than non-users (18.2%, 21.4% vs. 14.8%). The relative risk was 1.40 (95% confidence interval 0.94-2.10) for standard-term users and 1.70 (1.11-2.59) for long-term users. Tamoxifen use was unrelated to frequency of glaucoma or macular degeneration or to Amsler grid test results. INTERPRETATION: Our study suggests that five or more years of tamoxifen use increases risk of cataracts. Healthy women considering tamoxifen use to reduce risk of breast cancer should be advised of the possibility of cataract development. Women choosing such therapy should be diligent about receiving regular ocular exams.
30 schema:genre research_article
31 schema:inLanguage en
32 schema:isAccessibleForFree false
33 schema:isPartOf N33cd0f079b854adb8b863bf6763ef5f0
34 Nb5bb8ac5380446478fd8406eea78220b
35 sg:journal.1092777
36 schema:name Eye problems in breast cancer patients treated with tamoxifen
37 schema:pagination 167-172
38 schema:productId N16f8c01639f4428a8d38c7459af387d3
39 N333bb3897b3d4fe7a27f66a828661e24
40 N7578d4e4add345318e8d52ee0be2f3bb
41 Na7c78c90193e417bb3365d2e48c28d3d
42 Nfd6236f8ed544ebd8f4fd242c963f585
43 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053062817
44 https://doi.org/10.1023/a:1006342300291
45 schema:sdDatePublished 2019-04-10T14:07
46 schema:sdLicense https://scigraph.springernature.com/explorer/license/
47 schema:sdPublisher N6c774c6a6d014235a3c220865cd2e69a
48 schema:url http://link.springer.com/10.1023/A:1006342300291
49 sgo:license sg:explorer/license/
50 sgo:sdDataset articles
51 rdf:type schema:ScholarlyArticle
52 N01d1127c67d2487eb3ea22969f8b5049 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
53 schema:name Tamoxifen
54 rdf:type schema:DefinedTerm
55 N094cd4ea599c42f9bcb472c2ab72e622 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
56 schema:name Risk Assessment
57 rdf:type schema:DefinedTerm
58 N16f8c01639f4428a8d38c7459af387d3 schema:name nlm_unique_id
59 schema:value 8111104
60 rdf:type schema:PropertyValue
61 N19787cf257cc4bc088e9c30366ea45c1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
62 schema:name Middle Aged
63 rdf:type schema:DefinedTerm
64 N21af17255b354a038d2406c188db2abb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Female
66 rdf:type schema:DefinedTerm
67 N333bb3897b3d4fe7a27f66a828661e24 schema:name dimensions_id
68 schema:value pub.1053062817
69 rdf:type schema:PropertyValue
70 N33cd0f079b854adb8b863bf6763ef5f0 schema:issueNumber 2
71 rdf:type schema:PublicationIssue
72 N4d432ef656f84dd1bafe1537c1d8beac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Humans
74 rdf:type schema:DefinedTerm
75 N58aebe3050354f03a8a85684ab93c2de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name Eye Diseases
77 rdf:type schema:DefinedTerm
78 N64cc18f63a7f4ce6a89587c58b3c43b3 rdf:first sg:person.01334140055.98
79 rdf:rest rdf:nil
80 N6c774c6a6d014235a3c220865cd2e69a schema:name Springer Nature - SN SciGraph project
81 rdf:type schema:Organization
82 N73e636f6294446ef980bcd2ab12e2a78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Incidence
84 rdf:type schema:DefinedTerm
85 N74c5220cf7b542d2bcba6059111ab061 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Cataract
87 rdf:type schema:DefinedTerm
88 N7578d4e4add345318e8d52ee0be2f3bb schema:name pubmed_id
89 schema:value 10845279
90 rdf:type schema:PropertyValue
91 Na7c78c90193e417bb3365d2e48c28d3d schema:name doi
92 schema:value 10.1023/a:1006342300291
93 rdf:type schema:PropertyValue
94 Nb5bb8ac5380446478fd8406eea78220b schema:volumeNumber 60
95 rdf:type schema:PublicationVolume
96 Nbaad2ec05ff8489c9a828d99a285eaa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Time Factors
98 rdf:type schema:DefinedTerm
99 Nbda3adc2fc9e4dee9ed65dcdd3b40497 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Aged
101 rdf:type schema:DefinedTerm
102 Nbe028a703c4843f1b92e98266a777abb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Antineoplastic Agents, Hormonal
104 rdf:type schema:DefinedTerm
105 Ncb5ca8143ab3498a935f2b92bbe71a52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Follow-Up Studies
107 rdf:type schema:DefinedTerm
108 Ndc4f845b77a348b786f3b2620d0c9d55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Breast Neoplasms
110 rdf:type schema:DefinedTerm
111 Nfd6236f8ed544ebd8f4fd242c963f585 schema:name readcube_id
112 schema:value fcc040a36559c19b4d5bc426f40477dc0236d46a2f94e2e29c1790b94065afee
113 rdf:type schema:PropertyValue
114 Nfeee8d56457b4e79b3c1e7ada06e4961 rdf:first sg:person.01032313301.19
115 rdf:rest N64cc18f63a7f4ce6a89587c58b3c43b3
116 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
117 schema:name Medical and Health Sciences
118 rdf:type schema:DefinedTerm
119 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
120 schema:name Public Health and Health Services
121 rdf:type schema:DefinedTerm
122 sg:grant.2435384 http://pending.schema.org/fundedItem sg:pub.10.1023/a:1006342300291
123 rdf:type schema:MonetaryGrant
124 sg:journal.1092777 schema:issn 0167-6806
125 1573-7217
126 schema:name Breast Cancer Research and Treatment
127 rdf:type schema:Periodical
128 sg:person.01032313301.19 schema:affiliation https://www.grid.ac/institutes/grid.42505.36
129 schema:familyName Paganini-Hill
130 schema:givenName Annlia
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032313301.19
132 rdf:type schema:Person
133 sg:person.01334140055.98 schema:affiliation https://www.grid.ac/institutes/grid.42505.36
134 schema:familyName Clark
135 schema:givenName Linda J
136 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334140055.98
137 rdf:type schema:Person
138 https://app.dimensions.ai/details/publication/pub.1081767724 schema:CreativeWork
139 https://app.dimensions.ai/details/publication/pub.1082773348 schema:CreativeWork
140 https://app.dimensions.ai/details/publication/pub.1083051131 schema:CreativeWork
141 https://doi.org/10.1016/0042-6989(94)90099-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1039738451
142 rdf:type schema:CreativeWork
143 https://doi.org/10.1016/s0002-9394(99)80190-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049049615
144 rdf:type schema:CreativeWork
145 https://doi.org/10.1016/s0161-6420(96)30431-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039249711
146 rdf:type schema:CreativeWork
147 https://doi.org/10.1093/jnci/90.18.1371 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049883062
148 rdf:type schema:CreativeWork
149 https://doi.org/10.1097/00006254-200007000-00022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1060260386
150 rdf:type schema:CreativeWork
151 https://doi.org/10.1172/jci117514 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018622434
152 rdf:type schema:CreativeWork
153 https://doi.org/10.1200/jco.1996.14.3.1018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082882762
154 rdf:type schema:CreativeWork
155 https://www.grid.ac/institutes/grid.42505.36 schema:alternateName University of Southern California
156 schema:name Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
157 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...